polyclonal antibodies pabs antibodies secreted different b cell lineages within body whereas monoclonal antibodies come single cell lineage collection immunoglobulin molecules react specific antigen identifying different epitope general procedure produce polyclonal antibodies follows antigenadjuvant conjugate injected animal choice initiate amplified immune response series injections specific length time animal expected created antibodies conjugate blood extracted animal purified obtain antibody interest inoculation performed suitable mammal mouse rabbit goat larger mammals often preferred amount serum collected greater antigen injected mammal induces blymphocytes produce igg immunoglobulins specific antigen polyclonal igg purified mammals serum contrast monoclonal antibodies derived single cell line many methodologies exist polyclonal antibody production laboratory animals institutional guidelines governing animal use procedures relating methodologies generally oriented around humane considerations appropriate conduct adjuvant agents modify effect agents direct effects given use includes adjuvant selection routes sites administration injection volumes per site number sites per animal institutional policies generally include allowable volumes blood per collection safety precautions including appropriate restraint sedation anesthesia animals injury prevention animals personnel primary goal antibody production laboratory animals obtain high titer high affinity antisera use experimentation diagnostic tests adjuvants used improve enhance immune response antigens adjuvants provide injection site antigen depot allows slow release antigen draining lymph nodes many adjuvants also contain act directly antigens generally poor immunogens complex protein antigens induce multiple bcell clones immune response thus response polyclonal immune responses nonprotein antigens generally poorly enhanced adjuvants system memory antibodies currently also produced isolation human blymphocytes produce specific recombinant monoclonal antibody mixtures biotechnology company symphogen develops type antibodies therapeutic applications first research company reach phase two trials monoclonal antibody mixtures mimic diversity polyclonal antibody drugs production prevents viral prion transmission simple process animals frequently used polyclonal antibody production include chickens goats guinea pigs hamsters horses mice rats sheep however rabbit commonly used laboratory animal purpose animal selection based upon goats horses generally used large quantities antisera required many investigators favor chickens phylogenetic distance mammals chickens transfer high quantities igy igg egg yolk harvesting antibodies eggs eliminates need invasive bleeding procedure one weeks eggs contain times antibodies volume rabbit blood obtained one weekly bleeding however disadvantages using certain chicken derived antibodies immunoassays chicken igy fix mammalian complement component perform precipitating antibody using standard solutions although mice used frequently monoclonal antibody production small size usually prevents use sufficient quantities polyclonal serum antibodies however polyclonal antibodies mice collected ascites fluid using one number ascites producing methodologies using rabbits young adult animals kg lbs used primary immunization vigorous antibody response immune function peaks puberty primary responses new antigens decline age female rabbits generally preferred docile reported mount vigorous immune response males least two animals per antigen used using outbred animals principle reduces potential total failure resulting nonresponsiveness antigens individual animals size extent aggregation relative nativity protein antigens dramatically affect quality quantity antibody produced small polypeptides ku nonprotein antigens generally need conjugated crosslinked larger immunogenic carrier proteins increase immunogenicity provide cell epitopes generally larger immunogenic protein better larger proteins even smaller amounts usually result better engagement antigen presenting antigen processing cells satisfactory immune response injection soluble nonaggregated proteins higher probability inducing tolerance rather satisfactory antibody response keyhole limpet hemocyanin klh bovine serum albumin two widely used carrier proteins polyllysine also used successfully backbone peptides although use polyllysine reduces eliminates production antibodies foreign proteins may result failure peptideinduced antibody production recently liposomes also successfully used delivery small peptides technique alternative delivery oily emulsion adjuvants selection antigen quantity immunization varies properties antigen adjuvant selected general microgram milligram quantities protein adjuvant necessary elicit high titer antibodies antigen dosage generally species rather body weight associated socalled window immunogenicity species broad much little antigen induce tolerance suppression immune deviation towards cellular immunity rather satisfactory humoral response optimal usual protein antigen levels immunizing specific species reported following ranges optimal priming doses reported low end range affinity serum antibodies increases time months injection antigenadjuvant mixtures antigen system decreases widely used antigen dosages booster secondary immunizations usually one half equal priming dosages antigens free preparative byproducts chemicals polyacrylamide gel sds urea endotoxin particulate matter extremes ph peptide used generate antibody extremely important design antigens properly several resources aid design well companies offer service expasy aggregated set public tools protscale page require degree user knowledge navigate simple peptide scoring tool antigen profiler tool available enable score individual peptide sequences based upon relation epitope mapping database previous immunogens used generate antibodies finally general rule peptides follow basic criteria examining peptides synthesis immunization recommended certain residues sequences avoided due potential synthesis problems includes common characteristics investigators also consider status nativity protein antigens used immunogens reaction antibodies produced antibodies native proteins react best native proteins antibodies denatured proteins react best denatured proteins elicited antibodies used membrane blots proteins subjected denaturing conditions antibodies made denatured proteins hand antibodies used react native protein block protein active site antibodies made native protein adjuvants often alter nativity protein generally absorbed protein antigens preformed oilinwater emulsion adjuvant retain greater native protein structure waterinoil emulsions antigens always prepared using techniques ensure free microbial contamination protein antigen preparations sterilized passage filter septic abscesses often occur inoculation sites animals contaminated preparations used result failure immunization targeted antigen many commercially available immunologic adjuvants selection specific adjuvants types varies depending upon whether used research antibody production vaccine development adjuvants vaccine use need produce protective antibodies good systemic memory antiserum production need rapidly induce high titer high avidity antibodies single adjuvant ideal purposes advantages disadvantages adjuvant use generally accompanied undesirable side effects varying severity duration research new adjuvants focuses substances minimal toxicity retaining maximum immunostimulation investigators always aware potential pain distress associated adjuvant use laboratory animals frequently used adjuvants antibody production freunds alum ribi adjuvant system titermax two basic types freunds adjuvants freunds complete adjuvant fca freunds incomplete adjuvant fia fca waterinoil emulsion localizes antigen release periods months formulated mineral oil surfactant mannide monoleate heat killed mycobacterium tuberculosis mycobacterium butyricum extracts aggregation macrophages inoculation site potent adjuvant stimulates cell mediated humoral immunity preferential induction antibody epitopes denatured proteins although fca historically widely used adjuvant one toxic agents due nonmetabolizable mineral oil induces granulomatous reactions use limited laboratory animals used weak antigens used single animal since multiple fca inoculations cause severe systemic reactions decreased immune responses freunds incomplete adjuvant formulation fca contain mycobacterium components fia usually limited booster doses antigen since normally much less effective fca primary antibody induction freunds adjuvants normally mixed equal parts antigen preparations form stable emulsions ribi adjuvants oilinwater emulsions antigens mixed small volumes metabolizable oil squalene emulsified saline containing surfactant polysorbate system also contains refined mycobacterial products cord factor cell wall skeleton immunostimulants bacterial monophosphoryl lipid three different species oriented formulations adjuvant system available adjuvants interact membranes immune cells resulting cytokine induction enhances antigen uptake processing presentation adjuvant system much less toxic less potent fca generally induces satisfactory amounts high avidity antibodies protein antigens titermax represents newer generation adjuvants less toxic contain biologically derived materials based upon mixtures surfactant acting linear blocks chains nonionic copolymers polyoxypropylene pop polyoxyethylene poe copolymers less toxic many surfactant materials potent adjuvant properties favor chemotaxis complement activation antibody production titermax adjuvant forms microparticulate waterinoil emulsion copolymer metabolizable squalene oil copolymer coated emulsion stabilizing silica particles allows incorporation large amounts wide variety antigenic materials adjuvant active copolymer forms hydrophilic surfaces activate complement immune cells increased expression class ii major histocompatibility molecules macrophages titermax presents antigen highly concentrated form immune system often results antibody titers comparable higher fca specol specol water oil adjuvant made purified mineral oil reported induce immune response comparable freunds adjuvant rabbit research animal producing fewer histological lesions digoxin immune fab antigen binding fragment polyclonal antibodies raised digitalis derivative hapten bound protein used reversal lifethreatening digoxin digitoxin rhod immune globulin made pooled human plasma provided rhnegative donors antibodies antigen used provide passive immune binding antigen preventing maternal active immune response could potentially result hemolytic disease rozrolimupab antirhd recombinant human polyclonal antibody composed unique antibodies used treatment immune thrombocytopenia purpura prevention isoimmunization rhnegative pregnant women regeneron pharmaceuticals potential treatment people prevent coronavirus infection use polyclonal antibodies pabs monoclonal antibodies advantages technical skills needed produce polyclonal antibodies demanding theyre inexpensive make generated fairly quickly taking several months produce pabs heterogeneous allows bind wide range antigen epitopes pabs produced large number b cell clones theyre likely successfully bind specific antigen pabs remain stable different environments change ph salt concentration allows applicable certain procedures additionally depending amount needed pabs made large quantities relation size animal httpsenwikipediaorgwikipolyclonalantibodies